Prescription medicines

The product portfolio of this division includes leading prescription medicines such as the cancer drug Erbitux® (marketed outside the U.S.) and the multiple sclerosis treatment Rebif®. In addition, we offer therapies to treat infertility, growth disorders, cardiovascular and metabolic diseases. Reseach and development activities focus on the core therapeutic areas of oncology, neurodegenerative diseases and rheumatology.
Our enduring commitment and focus in specialist indications enable the division to deliver targeted medicines and innovative drug delivery systems to patients all over the world. We generate 60% of our sales with our five top-selling biopharmaceuticals. In medical biotechnology, we are the leader in Europe. In order to further expand this position, we are currently expanding Europe’s most modern biotechnology manufacturing facility, located in Switzerland.
 
Headquarter of EMD Serono Inc. in Rockland, MA
Headquarter of EMD Serono in Rockland, MA
Key products by therapeutic area
Therapeutic Area Key Products
Oncology
  • Erbitux® (solid tumors)
  • UFT®
Neurodegenerative Diseases
Fertility
Endocrinology
CardioMetabolic Care
  • Glucophage® franchise (type 2 diabetes)
  • Concor® franchise (cardiovascular diseases)
  • Euthyrox® (thyroid diseases)

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
 

DIVISION SITE

www.emdserono.com

CLINICAL TRIALS

Clinical Trials
For information on clinical trials currently being conducted in the framework of our development projects, please click here.